logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Sorrento Therapeutics, Inc.

Calculating rank
USPTO Granted Patents = 114

% Expired Patents = 16.7



Trademarks = 6

Forward Citations = 426

Loading Chart...
Loading Chart...

64 inventors (with patents filed for the assignee):

goldMedal Heyue Zhou (56 out of 62 patents)

silverMedal Russell Frederick Ross (39 out of 72 patents)

bronzeMedal John Dixon Gray (33 out of 57 patents)

4.  Luke Hagan (21 out of 33 patents)

5.  Gunnar F Kaufmann (20 out of 22 patents)

6.  Barbara Anne Swanson (20 out of 27 patents)

7.  Andrew Thomas Baker (18 out of 55 patents)

8.  Randy Gastwirt (12 out of 13 patents)

9.  Elizabeth Deibler Gadsby (11 out of 37 patents)

10.  Edwige Gros (10 out of 10 patents)

11.  Guodi Lu (9 out of 10 patents)

12.  Yanwen Fu (8 out of 11 patents)

13.  Dingqiu Huang (7 out of 7 patents)

14.  Aaron Peck (6 out of 8 patents)

15.  Alyson Yamada (6 out of 7 patents)


Core Competencies:
Antibody Therapeutics
Fluid Delivery Systems
Transdermal Drug Delivery
Nanopatterned Medical Devices
Chimeric Antigen Receptors
Antigen Binding Proteins
Microneedle Arrays
Bioactive Agents
Drug Conjugates
Immune Checkpoint Inhibitors
Delivery Apparatus
Cell Internalizing Compounds

114 patents:

1. 12624103 - Engineered Antibodies That Bind LAG3 (2026-05-12),
2. 12607589 - Methods, assays and systems for detection of a target analyte (2026-04-21),
3. 12017031 - Nanopatterned medical device with enhanced cellular interaction (2024-06-25),
4. 11925712 - Implantable devices for delivery of bioactive agents (2024-03-12),
5. 11883628 - Application device for a fluid delivery apparatus and method of use (2024-01-30),
6. 11883622 - Transdermal drug delivery device (2024-01-30),
7. 11878058 - Antigen binding proteins that bind PD-L1 (2024-01-23),
8. 11773177 - Variant antibodies that bind OX40 (2023-10-03),
9. 11760806 - CD-38 directed chimeric antigen receptor constructs (2023-09-19),
10. 11746156 - Antibody therapeutics that bind CD123 (2023-09-05),
11. 11745002 - Microneedle array assembly and fluid delivery apparatus having such an assembly (2023-09-05),
12. 11623962 - Anti-OX40 binding proteins (2023-04-11),
13. 11607457 - Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same (2023-03-21),
14. 11577023 - Application device for a fluid delivery apparatus and method of use (2023-02-14),
15. 11565098 - Device for delivery of rheumatoid arthritis medication (2023-01-31),
Company Overview
Sorrento Therapeutics, Inc. is a biotechnology company based in San Diego, California, specializing in the development of innovative antibody therapeutics. The company focuses on a range of advanced technologies, including fluid delivery systems, transdermal drug delivery, and nanostructured medical devices. Sorrento's expertise extends to chimeric antigen receptors and antigen binding proteins, as well as microneedle arrays and bioactive agents, positioning it at the forefront of therapeutic advancements in the biopharmaceutical sector.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Sorrento Therapeutics, Inc. USPTO Patent Assignee Logo
114 Patents

#51 in San Diego, CA

#762 in California

#3,373 in US

#6,954 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Sorrento Therapeutics, Inc.

Forward Citations = 426

64 inventors:

goldMedal Heyue Zhou (56 out of 62 patents)

silverMedal Russell Frederick Ross (39 out of 72 patents)

bronzeMedal John Dixon Gray (33 out of 57 patents)

4.  Luke Hagan (21 out of 33 patents)

5.  Gunnar F Kaufmann (20 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sorrento Therapeutics, Inc.. Retrieved from https://idiyas.com/company/sorrento-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…